Overview of Cerliponase Alfa's Approval in the European Market

The European Medicines Agency (EMA) has officially approved Brineura (cerliponase alfa), a treatment for CLN2 disease (late-infantile neuronal ceroid lipofuscinosis), developed by BioMarin Pharmaceutical (BMRN). The approval, granted on May 30, 2017, makes Brineura the first human recombinant enzyme replacement therapy (ERT) to directly replace the deficient tripeptidyl peptidase 1 (TPP1) enzyme. It is administered via an intracerebroventricular device, directly injecting the drug into the patient's cerebrospinal fluid (CSF). This represents a significant milestone, offering a real treatment option for patients with this ultra-rare genetic disorder, which has a high unmet medical need.

CLN2 Clinical Data and Medical Community Response

CLN2 is a rare and fatal genetic brain disorder, affecting fewer than 1 in 1 million people. Without treatment, it leads to rapid cognitive and motor decline. Clinical trials (Phase 1/2) showed that 94% of patients receiving Brineura maintained stable motor and language function for 48 to 96 weeks. This is a significant improvement over the previous standard of care, which relied solely on supportive and palliative care, as Brineura slows the progression of the disease. The medical community has noted the regulatory agency's official recognition of the safety and efficacy of the complex administration technique, which bypasses the blood-brain barrier (BBB) and delivers the drug directly into the ventricles.

High Pricing and Revenue Trends Due to Market Exclusivity

Brineura, launched in the European Union (EU) market, is positioned as an ultra-orphan drug with a high list price of approximately $702,000 per year (approximately $27,000 per dose). Due to its high cost, future revenue growth will depend on negotiations with national health authorities and reimbursement coverage. However, with its market exclusivity, Brineura's global revenue has shown steady growth, increasing from $169 million in 2024 to $186 million in 2025, representing a 10% increase. BioMarin is actively working to increase market penetration by offering various patient support programs and government discounts.

Global Regulatory Timeline and Competitive Pipeline

Following the European approval, BioMarin has continued to fulfill its obligations to submit regular long-term safety monitoring data and additional pediatric clinical data. In the United States, it received initial approval on April 27, 2017, and in July 2024, it expanded the indication to include children under the age of 3. Japan's PMDA also approved it on September 20, 2019. Currently, there are no direct competitors on the market, but next-generation gene therapy pipelines, such as Tern Therapeutics' TTX-181 (formerly REGENXBIO's RGX-181) and Latus Bio's LTS-101 (expected to receive IND approval and Fast Track designation by the end of 2025), are in clinical development and are beginning to challenge the market.